Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
3.520
+0.160 (4.76%)
Feb 21, 2025, 4:00 PM EST - Market closed
Scinai Immunotherapeutics Employees
Scinai Immunotherapeutics had 31 employees as of December 31, 2023. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$14,581
Profits / Employee
$151,484
Market Cap
3.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SCNI News
- 6 weeks ago - Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences - PRNewsWire
- 2 months ago - Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. - PRNewsWire
- 2 months ago - Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board - PRNewsWire
- 3 months ago - Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board - PRNewsWire
- 3 months ago - Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million - PRNewsWire
- 4 months ago - Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024 - PRNewsWire
- 5 months ago - Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies - PRNewsWire
- 5 months ago - IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. - GlobeNewsWire